Lisdexamfetamine prodrug activation by peptidase-mediated hydrolysis in the cytosol of red blood cells

Johannah Sharman, Michael Pennick Shire, Basingstoke, UK Abstract: Lisdexamfetamine dimesylate (LDX) is approved as a once-daily treatment for attention-deficit/hyperactivity disorder in children, adolescents, and adults in some countries. LDX is a prodrug comprising d-amphetamine covalently link...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sharman J, Pennick M
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://doaj.org/article/d3386f703dc14cf3962bea08b8cf1409
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares